The U.S. Food and Drug Administration (FDA) has proposed a new rule that could significantly restrict access to cheaper, compounded versions of popular weight-loss drugs like Ozempic and Wegovy.
This proposal aims to remove key GLP-1 ingredients—semaglutide, tirzepatide, and liraglutide—from the Section 503B “bulks list.” In simple terms, this closes a legal gray area that allowed large-scale compounding pharmacies to produce copies of these high-demand drugs, often at a lower cost. These facilities were able to do so primarily because of past drug shortages, which created a “clinical need.”
So, why is the FDA making this move now? The reasons are twofold. First, the critical shortages that once justified widespread compounding are largely over. Pharmaceutical giants Eli Lilly and Novo Nordisk have invested billions of dollars to expand their manufacturing capacity, stabilizing the supply of their branded drugs like Mounjaro, Zepbound, Ozempic, and Wegovy. With the official supply chain restored, the FDA's primary rationale for allowing compounding has disappeared.
Second, and just as importantly, are safety concerns. The FDA has repeatedly issued warnings about the risks associated with unapproved compounded drugs. These include reports of impurities, incorrect dosages, and counterfeit products that could pose a danger to patients. By formalizing this ban, the FDA is taking a decisive step to protect consumers and ensure that patients receive medications that meet federal quality and safety standards.
This regulatory shift is a significant win for Eli Lilly and Novo Nordisk. Patients who previously turned to compounded versions due to cost or availability will now be pushed toward the official, FDA-approved brands. Analysts estimate this could translate into more than $1 billion in additional annual revenue for these companies, split based on their market share. While the move is intended to enhance patient safety, it will likely lead to higher costs for consumers until insurance coverage for these expensive treatments becomes more widespread.
- GLP-1: Glucagon-like peptide-1 receptor agonists are a class of medications used to treat type 2 diabetes and obesity. They work by mimicking a hormone that regulates appetite and blood sugar.
- Compounded Drug: A medication that is custom-mixed by a pharmacist to meet an individual patient's specific needs. Regulations often allow for compounding when an FDA-approved drug is on the official shortage list.
- 503B Bulks List: A list of bulk drug substances (active ingredients) that FDA-registered “outsourcing facilities” can use to compound drugs without patient-specific prescriptions, typically to address a clinical need.